Diverse perspectives on science and medicine
CRISPR-Cas9 gene editing has been around not even 4 years, and people are avidly discussing its promises and perils (see “The Public and the Gene Editing Revolution” in today’s New England Journal of Medicine). That’s great. But
September will be 25 years since the first gene therapy experiment, and FDA approval is finally in sight. Several gene therapies are approaching the finish line, awaiting results from comparisons to existing therapies and analyses
Beneath all the bad news about viruses this week lies a good virus: the one that underlies gene therapy for X-linked severe combined immunodeficiency (SCID-X1). Altered viruses are the vehicles that transfer healthy human genes